{
    "root": "ab2be690-a801-46c1-a254-213c3893fc24",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound)",
    "value": "20250522",
    "ingredients": [
        {
            "name": "PACLITAXEL",
            "code": "P88XT4IS4D"
        },
        {
            "name": "ALBUMIN HUMAN",
            "code": "ZIF514RVZR"
        }
    ],
    "indications": "paclitaxel protein-bound particles injectable suspension ( albumin-bound ) microtubule inhibitor indicated treatment : • metastatic breast cancer , failure combination chemotherapy metastatic disease relapse within 6 months adjuvant chemotherapy . prior therapy included anthracycline unless clinically contraindicated . ( 1.1 ) • locally advanced metastatic non-small cell lung cancer ( nsclc ) , first-line treatment combination carboplatin , patients candidates curative surgery radiation therapy . ( 1.2 ) • metastatic adenocarcinoma pancreas first-line treatment , combination gemcitabine . ( 1.3 )",
    "contraindications": "substitute paclitaxel protein-bound particles injectable suspension ( albumin-bound ) paclitaxel products . ( 2.1 ) extravasation : closely monitor infusion site extravasation infiltration . ( 2.1 ) metastatic breast cancer ( mbc ) : recommended paclitaxel protein-bound particles injectable suspension ( albumin-bound ) 260 mg/m 2 intravenously 30 minutes every 3 weeks . ( 2.2 ) . non-small cell lung cancer ( nsclc ) : recommended paclitaxel protein-bound particles injectable suspension ( albumin-bound ) 100 mg/m 2 intravenously 30 minutes days 1 , 8 , 15 21-day cycle ; administer carboplatin day 1 21-day cycle immediately paclitaxel protein-bound particles injectable suspension ( albumin-bound ) . ( 2.2 ) adenocarcinoma pancreas : recommended paclitaxel protein-bound particles injectable suspension ( albumin-bound ) 125 mg/m 2 intravenously 30-40 minutes days 1 , 8 15 28-day cycle ; administer gemcitabine days 1 , 8 15 28-day cycle immediately paclitaxel protein-bound particles injectable suspension ( albumin-bound ) . ( 2.4 ) patients hepatic impairment : paclitaxel protein-bound particles injectable suspension ( albumin-bound ) recommended patients ast > 10 x uln ; bilirubin > 5 x uln metastatic adenocarcinoma pancreas moderate severe hepatic impairment . mbc nsclc , reduce starting dose patients moderate severe hepatic impairment . ( 2.5 ) dose reductions : dose reductions discontinuation may needed based severe hematologic , neurologic , cutaneous , gastrointestinal toxicities . ( 2.6 )",
    "warningsAndPrecautions": "paclitaxel protein-bound particles injectable suspension ( albumin-bound ) white yellow , sterile lyophilized powder supplied : ndc paclitaxel protein-bound particles injectable suspension ( albumin-bound ) package factor 71288-183-50 100 mg single-dose vial 1 vial per carton",
    "adverseReactions": "paclitaxel protein-bound particles injectable suspension ( albumin-bound ) contraindicated patients : • baseline neutrophil counts < 1,500 cells/mm3 [ ( 5.1 ) ] • history severe hypersensitivity paclitaxel protein-bound particles injectable suspension ( albumin-bound ) [ ( 5.5 ) ]",
    "indications_original": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is a microtubule inhibitor indicated for the treatment of: • Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.  Prior therapy should have included an anthracycline unless clinically contraindicated. ( 1.1 ) • Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. ( 1.2 ) • Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. ( 1.3 )",
    "contraindications_original": "Do not substitute paclitaxel protein-bound particles for injectable suspension (albumin-bound) for other paclitaxel products. (2.1) Extravasation : Closely monitor the infusion site for extravasation and infiltration. (2.1) Metastatic Breast Cancer (MBC) : Recommended dosage of paclitaxel protein-bound particles for injectable suspension (albumin-bound) is 260 mg/m 2 intravenously over 30 minutes every 3 weeks. (2.2). Non-Small Cell Lung Cancer (NSCLC) : Recommended dosage of paclitaxel protein-bound particles for injectable suspension (albumin-bound) is 100 mg/m 2 intravenously over 30 minutes on Days 1, 8, and 15 of each 21-day cycle; administer carboplatin on Day 1 of each 21-day cycle immediately after paclitaxel protein-bound particles for injectable suspension (albumin-bound). (2.2) Adenocarcinoma of the Pancreas : Recommended dosage of paclitaxel protein-bound particles for injectable suspension (albumin-bound) is 125 mg/m 2 intravenously over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle; administer gemcitabine on Days 1, 8 and 15 of each 28-day cycle immediately after paclitaxel protein-bound particles for injectable suspension (albumin-bound). (2.4) Use in patients with Hepatic Impairment : Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is not recommended for use in patients with AST > 10 x ULN; or bilirubin > 5 x ULN or with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment. For MBC or NSCLC, reduce starting dose in patients with moderate to severe hepatic impairment. (2.5) Dose Reductions for Adverse Reactions : Dose reductions or discontinuation may be needed based on severe hematologic, neurologic, cutaneous, or gastrointestinal toxicities. (2.6)",
    "warningsAndPrecautions_original": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is a white to yellow, sterile lyophilized powder supplied as:\n                  \n                     \n                     \n                        \n                           \n                              NDC\n                           \n                           \n                              Paclitaxel protein-bound particles for injectable suspension (albumin-bound) \n                           \n                           \n                              Package Factor \n                           \n                        \n                        \n                           71288-183-50 \n                           100 mg Single-Dose Vial\n                           1 vial per carton",
    "adverseReactions_original": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is contraindicated in patients with:\n            \n                  \n                     \n                        •\n                Baseline neutrophil counts of < 1,500 cells/mm3\n                        [see Warnings and Precautions (5.1)]\n                \n                     \n                     \n                        •\n                A history of severe hypersensitivity reactions to paclitaxel protein-bound particles for injectable suspension (albumin-bound) [see Warnings and Precautions (5.5)]"
}